ERBB2 and breast cancer: Agostinetto et al. [22] performed an analysis of the PAM50 intrinsic subtype for the heterogeneous disease of HER2-low expressing BC and highlighted differences in the clinical outcomes of this subtype and HER2 zero expressing BC.